BeiGene Announces Positive Global Phase 3 Trial Results for PD-1 Inhibitor Tislelizumab in First-Line Unresectable Hepatocellular Cancer - BeiGene Australia

Australia
- Australia
- Canada EN|FR
- China
- Germany
- Global
- Spain
- US

https://ir.beigene.com/news-details/?id=65d92c44-3f6f-4a00-9433-52c144854bbc

You will be redirected to

Click the link above to continue or CANCEL